Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company ...

Is the F.A.A. really ensuring safety by disqualifying pilots who receive a diagnosis or treatment? Troy Merritt, a pilot, ...

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

Mark Millich, 26 years old and insecure about his thinning hair, was curious about the ads he saw promising to reverse his ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

U.S. District Judge M. Casey Rodgers, accused in a misconduct complaint two weeks ago of showing preference to women, gave ...

Step right up, ladies and gentlemen, and welcome to the hottest new spot in town: The Weight-Loss Casino! Here, you don’t ...

Hims & Hers Health ( HIMS -7.38%) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target ...

Hims & Hers app downloads surged 47% in February. Demand for GLP-1 weight-loss drugs is the most likely reason for the growth. But sales of such weight loss drugs are going away soon, and the ...

Hims & Hers Health (NYSE: HIMS) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach delivered some good news for the mail-order drugs stock. Citing third ...

RKLX, the Defiance Daily Target 2X Long RKLB ETF , seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab , a company at the forefront of satellite ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing hair-loss treatments to young men without adequately flagging up some ...